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Abstract: The term emergency contraception (EC) refers to utilizing a medication or placing a 
copper intrauterine device within a short time interval after unprotected intercourse in order to 
prevent pregnancy. Established methods of EC include the Yuzpe regimen, levonorgestrel, and 
placement of a copper intrauterine device. Recently, ulipristal acetate, a selective progesterone 
receptor modulator, has been examined in several large-scale clinical trials and been shown to 
have comparable if not improved efficacy over the levonorgestrel regimen, which is the most 
commonly used form of EC today. EC has increased in efficacy since its advent with the Yuzpe 
regimen several decades ago, and many have expressed hope that widespread utilization of EC 
will lead to a decreased abortion rate worldwide. However, despite increased access to EC over 
the past several years, many barriers still exist in regards to allowing EC to be widely available 
to women wishing to prevent unplanned pregnancies. Future research must focus on addressing 
such barriers in order to realize the potential of EC to decrease abortion rates worldwide. This 
review article will address the current options for EC, describe current challenges in the field, 
and highlight future avenues of research.
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Introduction
In the US, it is estimated that approximately 50% of pregnancies are unintended, 
and about half of such unintended pregnancies end in abortion.1 Teen pregnancies 
contribute significantly to this number, with approximately 750,000 teens aged 
15–19 years becoming pregnant in the US each year. Minority populations, most 
notably African Americans and Hispanics, contribute disproportionately to such 
unintended pregnancies.2 The unplanned pregnancy rate worldwide is not much better; 
of the 210 million established pregnancies each year, about 40% are unintended.3 
Such statistics point to the importance of making emergency contraception (EC) 
widely available and easily accessible to women to provide a means to help reduce the 
unintended pregnancy rate. However, access to EC is not the only obstacle encountered 
in the campaign to decrease unintended pregnancies. This paper reviews the current 
EC options available today, challenges in making effective and efficient use of EC, 
and future directions of research.
Indications for EC
EC refers to utilizing a medication or placing a copper intrauterine device (IUD) within 
a short time interval after unprotected intercourse in order to prevent pregnancy. EC is 
also referred to as the “morning-after pill” or “post-coital contraception,” but experts 
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in the field discourage the use of such terminology for fear 
that it may breed confusion regarding the timing of when 
EC can be used.4 EC is indicated in situations where other 
contraceptive methods have failed or when no contraceptive 
method was used in women who do not desire pregnancy. 
Examples of contraceptive failure include when a condom 
breaks or slips, missing two or more doses of a combined oral 
contraceptive pill, taking a progestin-only pill more than three 
hours late, being more than two weeks late in repeat admin-
istration of depot medroxyprogesterone acetate, or when 
dislodgement or breakage of a barrier method  (diaphragm 
or cervical cap) occurs.5
One important fact for all women’s health providers to 
remember is that there are no absolute contraindications to 
EC for any woman of reproductive age desiring to prevent 
pregnancy. The World Health Organization (WHO) describes 
no medical circumstance in which the risks of EC outweigh 
the advantages of preventing pregnancy.6,7 Even in medical 
conditions for which combined oral contraceptives have 
been deemed contraindicated, such as cardiovascular disease, 
migraine, or liver disease, it is not necessary to withhold 
EC. Drug options for EC generally include levonorgestrel 
alone, the combined estrogen-progestin (Yuzpe) regimen, and 
selective progesterone receptor modulators-antiprogestins. 
However, accessibility of each of these regimens varies by 
country. The levonorgestrel regimen is currently the most 
widely available form of EC and is marketed specifically 
for this purpose. Placement of a copper IUD represents a 
mechanical option to avoid unwanted pregnancy following 
unprotected intercourse, and can also function as a long-term 
contraceptive method.
Yuzpe regimen
The idea of being able to prevent pregnancy after unprotected 
intercourse is not a novel concept and has been around for 
several decades. In the 1970s, the first effective means 
of postcoital contraception was introduced and involved 
administration of higher doses of combined oral contraceptive 
pills containing ethinyl estradiol and either levonorgestrel or 
norgestrel. This initial development in the field of EC is 
accredited to Dr Albert Yuzpe, a Canadian physician who 
described the use of a combination of ethinyl estradiol 0.2 mg 
with norgestrel 2 mg taken in two divided doses 12 hours 
apart, with the first dose administered within 72 hours 
following unprotected intercourse.8 In one series of 608 
patients, only one patient became pregnant from presumed 
method failure.8 This regimen became coined the “Yuzpe 
regimen,” and was very popular back in the 70s and 80s.
However, as described in more detail below, subsequent 
studies have demonstrated the levonorgestrel regimen to 
be more effective with fewer side effects,9 so the Yuzpe 
regimen is no longer the first-line recommendation for 
EC. Given the relatively high doses of ethinyl estradiol in 
the Yuzpe  regimen, common side effects include nausea 
and vomiting, with reported incidences close to 50% and 
20%, respectively.9 Indeed, it is often recommended that 
women take an antiemetic in conjunction with the Yuzpe 
regimen, given the high incidence of gastrointestinal side 
effects.  However, one benefit to the Yuzpe regimen is that 
the appropriate doses of ethinyl estradiol and levonorgestrel 
or norgestrel can be obtained through a variety of combined 
oral contraceptive pills on the market today. Thus, for 
women who feel uncomfortable seeking medication for EC 
purposes or have privacy concerns, the Yuzpe regimen could 
potentially be used with combined oral contraceptive pills 
they already take for long-term contraception. Additionally, 
in some  countries with restricted licensing of other EC 
methods, the Yuzpe regimen may be the only available EC 
option available to women wishing to prevent an undesired 
pregnancy.10
Levonorgestrel
Efficacy
In the original studies, the levonorgestrel regimen, marketed 
as plan B® in the US, was studied as two doses of levonorg-
estrel 0.75 mg taken 12 hours apart. In a landmark study, 
this levonorgestrel regimen was compared with the more 
traditional Yuzpe regimen and was demonstrated to have com-
parable efficacy when taken within 72 hours of unprotected 
intercourse (failure rate 2.4% in the levonorgestrel group 
versus 2.6% in the Yuzpe group) as well as an improved side 
effect profile.11 Indeed, the incidence of nausea,  vomiting, 
and fatigue was significantly lower in the group treated with 
levonorgestrel alone. A second, larger, randomized, double-
blind controlled trial enrolling just under 2000 women at 
21 centers repeated the comparison of the levonorgestrel 
regimen taken within 72 hours following unprotected inter-
course with the Yuzpe regimen and demonstrated the superi-
ority of the levonorgestrel regimen (pregnancy rate 1.1% in 
the levonorgestrel group versus 3.2% in the Yuzpe group).9 
By estimating the expected number of pregnancies if EC had 
not been used, the authors concluded that the levonorgestrel 
regimen was 85% effective in preventing pregnancy.
More recent studies have demonstrated that a single 
1.5 mg dose of levonorgestrel was as effective as the 
0.75 mg divided dose regimen without changing the side 
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effect profile.12,13 Additionally, in the large trial conducted by 
the WHO in 2002 using a three-arm comparison of the two 
levonorgestrel dosing regimens as well as a single 10 mg 
dose of mifepristone, the investigators demonstrated that all 
regimens retained some efficacy up to 120 hours following 
unprotected intercourse.13 Currently, plan B One Step® (the 
single 1.5 mg dose of levonorgestrel) is licensed in the US to 
be used within 72 hours of unprotected intercourse.
Interestingly, the reported efficacy of the levonorgestrel 
regimen has recently been suggested to have been somewhat 
inflated in earlier studies due to the way in which the expected 
number of pregnancies was determined. Given that no trial 
for EC has ever randomized women to a placebo group 
where no medication was given, and it would be unethical 
to do so, studies to date have had to estimate the number of 
pregnancies prevented to determine the actual efficacy of EC 
methods. Some investigators have argued that the expected 
number of pregnancies used in some studies are based on 
conception rates in women who are attempting pregnancy, 
and for a variety of reasons, such conception rates are likely 
to be higher than in a population seeking EC.14 For example, 
some women seek EC following contraceptive failure, and 
the risk of pregnancy in this situation is likely to be less than 
if no contraception was used. Additionally, some trials have 
estimated the day of ovulation by counting backwards from 
the subsequent menses. Given that hormonal methods of EC 
can influence when menses begins, this is an inaccurate way 
to determine ovulation dating in these trials.
By using different estimates of pregnancy risk based on 
cycle day (where cycle day 1 is when menses begins in the 
cycle where EC is used), Trussell et al demonstrated that 
the efficacy rate for the Yuzpe regimen reported in two of 
the largest trials (conducted by the WHO and the Population 
Counsel)9,15 was likely overestimated by approximately 
10%.16 A follow-up study, using this new set of conception 
probabilities, argued that the levonorgestrel regimen prevents 
at least 49% of expected pregnancies if one makes the 
assumption that the Yuzpe regimen (its comparator) was 
completely ineffective at preventing pregnancy.14 However, 
given that there is good evidence that the Yuzpe regimen has 
some efficacy in preventing pregnancy following unprotected 
intercourse, it is likely that the levonorgestrel regimen 
actually prevents significantly more than 49% of expected 
pregnancies.
Mechanism of action
The mechanism through which the levonorgestrel regimen 
prevents pregnancy is thought to work primarily through 
disruption or delay in ovulation. Studies assessing follicular 
development and ovulation in association with timing 
of levonorgestrel administration have demonstrated that 
levonorgestrel is very effective at delaying or  blocking 
 ovulation when taken before the luteinizing hormone 
surge. However, once the luteinizing hormone surge has 
been initiated, levonorgestrel is not effective at disrupt-
ing ovulation.17–19 Although it has been debated whether 
the levonorgestrel regimen has other mechanisms through 
which it is able to prevent pregnancy, such as effects on 
sperm function, tubal transport, and endometrial receptiv-
ity, data to support such propositions have not been found.19 
In vitro studies have demonstrated that sperm function is 
not affected by the doses of levonorgestrel used in EC, and 
viable sperm have been found in the genital tract of women 
24–48 hours after taking levonorgestrel.20–22 Furthermore, 
several studies have now established that endometrial recep-
tivity does not appear to be affected by the levonorgestrel 
regimen.19,23,24
In an interesting study performed by Novikova et al 
women who presented for EC were treated with the single 
1.5 mg dose of levonorgestrel, and immediately before 
taking the medication, blood was drawn to assess timing of 
ovulation (via measurement of luteinizing hormone, estradiol, 
and progesterone).25 The authors demonstrated that, among 
women who had unprotected intercourse either the day 
prior to or on the day of ovulation, 3–4 pregnancies would 
be anticipated, and three pregnancies resulted. The women 
in this group took levonorgestrel approximately 2 days 
after ovulation. However, in women who had unprotected 
intercourse 2–5 days prior to ovulation, and thus took 
levonorgestrel prior to ovulation, four pregnancies would 
be expected based on the number of women in the study, 
but no pregnancies were observed. This study lends clinical 
support to the idea that ovulation is effectively delayed or 
inhibited when levonorgestrel is taken after recruitment of 
a dominant follicle but prior to initiation of the luteinizing 
hormone surge. However, the levonorgestrel regimen appears 
to have little to no effect in pregnancy prevention when 
taken after the onset of the luteinizing hormone surge. Thus, 
the levonorgestrel regimen has a fairly narrow therapeutic 
window during which it is efficacious.19 A similar study by 
Noe et al confirmed that levonorgestrel taken on or after the 
day of ovulation is ineffective in preventing pregnancy.26
Side effects
In general, the side effect profile of the levonorgestrel regimen 
is favorable, especially when compared with the  earlier 
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Yuzpe regimen. The most common side effects reported in 
the large trials included gastrointestinal symptoms, such as 
nausea, abdominal pain, vomiting, and diarrhea, with the 
incidence of nausea and vomiting being approximately 18% 
and 4%, respectively.7,9,12,13 Given the fairly low incidence 
of vomiting, routine use of antiemetics with the levonorg-
estrel regimen is not necessary. Additionally, side effects 
such as headache, fatigue, and dizziness, are occasionally 
reported.5,9,13 Menstrual irregularities and irregular bleeding 
have also been described in association with the use of the 
levonorgestrel regimen.
Generally, women will have their menstrual period 
within 1 week either before or after the expected time.9 
However, menstrual bleeding with levonorgestrel is 
delayed less frequently than it is when using progesterone 
receptor modulators, which is cited as a benefit of the 
levonorgestrel regimen, because delay in menses can 
often provoke anxiety about possible pregnancy. Indeed, 
in a randomized trial comparing ulipristal acetate, a 
progesterone receptor modulator, with the levonorgestrel 
regimen, menses was delayed by 2.1 days in the group who 
took ulipristal whereas the group who took levonorgestrel 
had menstrual bleeding 1.2 days earlier than expected.27 
Levonorgestrel can also cause nonmenstrual bleeding in 
the week after use.7,13 Irregular bleeding associated with 
EC is transient.
Precautions
Contraceptive medications are some of the most thoroughly 
studied drugs on the market today, and the safety of the 
levonorgestrel regimen has been well established. As 
mentioned earlier, there are no definitive contraindications 
to utilizing the levonorgestrel regimen for prevention of 
an unwanted pregnancy, and the WHO Medical Eligibility 
Criteria for Contraceptive Use lists no contraindications 
to the levonorgestrel system for EC.4,6 Indeed, the 
levonorgestrel regimen can currently be obtained in many 
countries without a prescription. However, it has been 
suggested that levonorgestrel may not be well absorbed in 
women with Crohn’s disease.4 Additionally, a theoretical 
risk exists that the standard dose may have decreased 
efficacy in women using medications that induce liver 
enzymes, such as antiepileptics, antiretrovirals, antifungals, 
and certain antibiotics. Some experts have suggested that 
women taking such medication should double the dose of 
levonorgestrel to 3 mg taken within 72 hours following 
unprotected intercourse, but there are no published data 
currently to back this recommendation.4 Finally, using 
the levonorgestrel system when a woman is known to be 
pregnant or suspects that she might be is a contraindication 
to its use. However, taking levonorgestrel with an established 
pregnancy will not disrupt the pregnancy, and it is not 
associated with an increased risk of birth defects if taken 
during pregnancy.5,7,28
Counseling points
As discussed further below, one of the challenges to 
 making EC more widely utilized is the lack of knowledge 
on the part of both women and, to some degree, women’s 
health  providers, regarding its use. When discussing the 
levonorgestrel regimen for EC with patients, it is important 
for providers to emphasize the following points:
•	 The levonorgestrel regimen is most effective when taken 
as soon as possible following unprotected intercourse. 
Some evidence suggests that efficacy decreases with 
increasing time between unprotected intercourse and 
taking the medication.11,13
•	 Because delay in ovulation is the primary mechanism 
through which levonorgestrel acts, patients must be 
warned that they are at continued risk of pregnancy if 
they engage in additional acts of unprotected intercourse 
after taking levonorgestrel.
•	 The levonorgestrel regimen is not as effective at 
preventing pregnancy as other methods developed for 
long-term  contraception, and it should not be used as 
the only means of contraception.4,7 Patients should 
be  counseled to begin using an appropriate long-term 
 contraceptive method, or, if contraceptive failure 
occurred, patients should be advised about how to avoid 
such contraceptive failures in the future.
•	 Given that the levonorgestrel regimen does not protect 
against pregnancy with future acts of unprotected 
intercourse, even in the same menstrual cycle, patients 
should be counseled to begin a barrier contraceptive 
method immediately after taking levonorgestrel. 
Additionally, hormonal contraceptive methods such 
as combined oral contraceptive pills can be started 
immediately after taking levonorgestrel, so long as a 
barrier method of contraception is also used until the next 
menstrual period. Longer-term hormonal options, such 
as the levonorgestrel IUD, depot medroxyprogesterone 
acetate (Depo-Provera®), or the progestin implant 
(Implanon®) should only be started after the patient’s next 
menstrual period to ensure that she is not pregnant.7
•	 There is no need for a scheduled follow-up visit after 
using the levonorgestrel regimen, but patients should be 
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advised that if their next menstrual period is delayed by a 
week or more that they should test for pregnancy.4,7
•	 The levonorgestrel regimen does not protect against sexu-
ally transmitted infections (STIs).4,5,7 In fact, no current 
method of EC protects against STIs.
Additionally, it is important for providers to keep in mind 
the following points when discussing or prescribing the 
levonorgestrel regimen for EC:
•	 No examination or screening tests are necessary to 
 prescribe the levonorgestrel regimen.7
•	 It is not necessary to obtain a pregnancy test routinely 
prior to prescribing levonorgestrel for EC.7 A pregnancy 
test should be sought only if there is reason to believe the 
patient may already be pregnant.
•	 Taking levonorgestrel will not interrupt an already estab-
lished pregnancy, and it is not associated with an increased 
risk of teratogenicity if taken during pregnancy.4,5,7
•	 The levonorgestrel regimen does not increase the risk of 
an ectopic pregnancy.5,7,29
•	 All women who are victims of sexual assault should be 
offered EC. Sadly, some studies have suggested that less 
than half of women who present to the emergency room 
in the US following sexual assault receive EC.7,30,31
Copper intrauterine device
Insertion of a copper IUD is another effective method of 
EC, and the indications for its use are the same as for other 
methods of EC. One touted benefit of utilizing the copper 
IUD as EC is that it has been shown to be quite effective 
in preventing pregnancy for up to 5 days after unprotected 
intercourse, or for up to 5 days following ovulation, whereas 
some studies have suggested decreasing efficacy over time 
with the levonorgestrel regimen.4,7,11,13 In addition, women 
can maintain the copper IUD as a long-term contraceptive 
method after placement, and studies have demonstrated that 
the vast majority of women who have a copper IUD placed 
for EC keep them in place for continued contraception.32 
 Additionally, some advocate the copper IUD as the 
mechanism of choice in women taking medications that can 
induce liver enzymes.4 However, one drawback to utilizing the 
copper IUD for EC is that it involves placement in a  clinical 
setting by a health care professional, thus necessitating that 
women present for evaluation and placement within a short 
time period following unprotected intercourse, limiting the 
availability of this option.
The copper IUD has been shown to be very effective in 
preventing pregnancy when placed within 5 days following 
unprotected intercourse, and prospective cohort trials have 
reported a pregnancy rate around 0%–0.2%.4,7,32,33 One 
mechanism through which the copper IUD acts to prevent 
pregnancy is via prevention of fertilization. Studies have 
demonstrated that the copper released is toxic to both sperm 
and ovulated oocytes, and it also acts at the level of the cervical 
mucus to decrease sperm penetration.4,34 Additionally, the 
copper IUD creates an inflammatory reaction within the 
endometrium, impairing implantation.4,35,36 Contraindications 
to utilizing the copper IUD as EC are the same as when used 
as routine contraception, and include a current STI or pelvic 
inflammatory disease.4 Nulliparity and young age are not 
contraindications. One question that often arises regarding 
placement of a copper IUD for EC is whether screening for 
STIs is necessary in this situation. Importantly, placement of 
the IUD should never be delayed in order to obtain culture 
results. In nonemergent situations, the WHO recommends 
performing an STI risk assessment prior to IUD placement. 
The Faculty of Sexual and Reproductive Healthcare of 
the Royal College of Obstetricians and Gynecologists 
recommends screening women for Chlamydia trachomatis 
prior to IUD insertion in women at risk and in all women 
who request screening.4 Some studies have suggested that 
positive Chlamydia cultures obtained at the time of IUD 
insertion are at low risk of developing pelvic inflammatory 
disease if the Chlamydia is treated with the IUD in place.37 
Finally, it is important to remember that it is only the copper 
IUD that can be utilized for EC, because the levonorgestrel 
IUD is not effective for this indication.4,7
Selective progesterone receptor 
modulation
One of the most recent medications to enter the EC arena is 
the progesterone receptor modulator, ulipristal acetate, which 
was approved by the US Food and Drug Administration (FDA) 
in August 2010 for use as an emergency contraceptive, and 
marketed under the trade name ella®. The same medication 
has been available in Europe, marketed under the name 
ellaOne®, since May 2009. Ulipristal acetate is a second-
generation progesterone receptor modulator.38 Mifepristone, 
a first-generation progesterone receptor modulator, is known 
to be quite efficacious at preventing pregnancy when taken 
as a single dose within 120 hours following unprotected 
intercourse.4,13,39 However, mifepristone is also used to induce 
medical abortions, and thus, for various social and political 
reasons, has not been approved for use as an emergency 
contraceptive agent in many countries.
In a large, randomized, controlled trial conducted 
by Crenin et al ulipristal acetate was found to be at least 
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as efficacious at preventing pregnancy as the split-dose 
levonorgestrel regimen when take within 72 hours following 
unprotected intercourse.38 Pregnancy rates of 0.9% and 1.7% 
were reported in the ulipristal acetate and levonorgestrel 
groups, respectively, demonstrating that 85% and 69% of 
pregnancies in each group were estimated to have been pre-
vented by the respective medications. A study performed by 
Fine et al examined the efficacy of ulipristal acetate in pre-
venting pregnancy when taken 48–120 hours after  unprotected 
intercourse, and reported a pregnancy rate of only 2.1% among 
1241 enrolled women.40 Moreover, the efficacy of ulipristal 
acetate did not diminish with increasing time of administration 
from unprotected intercourse, with reported pregnancy rates 
of 2.3%, 2.1%, and 1.3% in the 48–72-hour, 72–96-hour, and 
over 96-hour time intervals, respectively.
Finally, in a recent report, the efficacy of a 30 mg single 
dose of ulipristal acetate was compared head to head with a 
single 1.5 mg dose of levonorgestrel. The reported pregnancy 
rates were 1.8% and 2.6% in the ulipristal acetate and 
levonorgestrel groups, respectively, when the medications 
were taken within 72 hours of unprotected intercourse, a 
difference that was not statistically different.27 Furthermore, 
women who presented more than 72 hours after unprotected 
intercourse were also randomized, and in 203 women who 
received either ulipristal acetate or levonorgestrel between 
72 and 120 hours, three pregnancies were reported, all of 
which were in the levonorgestrel group. In this study, the 
authors also performed a meta-analysis, combining their 
study with the results reported by Crenin et al.38 Combination 
of the two studies increased the sample size dramatically, and 
in this combined analysis, ulipristal acetate decreased the risk 
of pregnancy by half when compared with levonorgestrel, 
demonstrating its superior eff icacy (odds ratio 0.55, 
confidence interval 0.32–0.93).27,41
Currently in the US, ulipristal acetate is licensed as an 
emergency contraceptive to be taken in a single 30 mg dose 
up to 5 days (120 hours) following unprotected intercourse, 
making it the only hormonal medication currently on the 
market approved for use up to 5 days following unprotected 
intercourse.42 The copper IUD is also efficacious up to 5 days 
following unprotected intercourse, but obviously requires 
that a woman present to a licensed care provider trained in 
inserting IUDs within this time interval, making it a less 
 convenient option. Side effects reported with ulipristal 
acetate have generally been mild, and include headache, 
nausea, and abdominal pain.40 The frequency with which 
such side effects are reported are comparable with those seen 
using the levonorgestrel regimen.40
Another consistent finding among the trials evaluating 
ulipristal acetate is that it causes a delay in the next menstrual 
cycle, which on average is approximately 2 days.38,40 This short 
menstrual delay has also been reported in conjunction with 
mifepristone, and has been touted as a downside of the proges-
terone receptor modulators as a class, because  menstrual delay 
may cause anxiety about a potential  pregnancy. However, with 
appropriate counseling by a health care professional, women 
can be reassured regarding this minor delay in the onset of 
menses, and should still be urged to seek a pregnancy test if 
their menstrual cycle is delayed by over 1 week.
Studies evaluating the mechanism through which ulipristal 
acetate inhibits pregnancy have shown that one mechanism of 
action is via inhibition of ovulation. In an interesting study 
by Brache et al women who were surgically sterilized were 
treated with a 30 mg dose of ulipristal acetate to determine 
its ability to block follicular rupture in the late follicular 
phase, once a lead follicle of 18 mm or greater was seen on 
ultrasonography.42 Additionally, serial luteinizing hormone, 
estradiol, and progesterone levels were assessed before and 
for five days after administration of ulipristal acetate. The 
authors demonstrated that follicular rupture was delayed for 
at least five days following ulipristal acetate administration in 
59% of cycles. Furthermore, when ulipristal acetate was given 
prior to the luteinizing hormone surge, follicular rupture was 
delayed 100% of the time, and when ulipristal acetate was 
given after initiation but prior to the peak of the luteinizing 
hormone surge, follicular rupture was blocked in 78.6% of 
cases. Only when ulipristal acetate was administered after 
the peak of the luteinizing hormone surge did it fail to block 
follicular rupture. In similar studies conducted by the same 
authors, levonorgestrel was able to delay follicle rupture in 
only 14.6% of cycles when administered with a lead follicle 
18 mm or greater, and this may account for the higher efficacy 
of ulipristal acetate in preventing pregnancy.18,43 The authors 
additionally commented that, although follicular rupture 
was delayed by 5 or more days in the majority of the women 
treated with ulipristal acetate, follicular rupture ultimately 
did occur at a later time point in the cycle, indicating that 
ulipristal acetate is effective in preventing pregnancy for up 
to 5 days after unprotected intercourse, but that if a woman 
has additional acts of coitus after taking ulipristal acetate, 
she is still at risk of pregnancy.42
Current challenges with emergency 
contraception
Efficient utilization of EC to prevent unwanted pregnancies 
is an example of the evolution of type 3 translational 
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research. Translational research generally describes the 
progression of taking discoveries in basic science and 
translating them into clinical medicine to promote the 
health of a population. Type 3 translational research 
specifically describes the process of taking a medication 
or intervention proven to be effective in large, randomized 
trials and implementing its routine use by the necessary 
cohort of physicians such that the population as a whole 
is exposed to and derives benefit from the medication 
and/or intervention. Addressing the question of why 
medications or interventions demonstrated to be effective 
in the research setting are not routinely utilized in large 
populations is the cornerstone of type 3 translational 
research, and is an important component of current research 
in EC. As discussed earlier, current EC regimens have 
been demonstrated to be highly effective in preventing 
pregnancy. However, despite the fact that specific EC 
products have been marketed in the US since the late 1990s, 
unintended pregnancy rates and abortion rates, both in 
the US and globally, have not changed significantly.10,44,45 
Indeed, a study describing the potential of EC projected 
that widespread utilization could decrease the abortion rate 
in the US by half.1 Thus, answering the question of why 
enhanced availability of EC has not impacted the incidence 
of unintended pregnancy as had been projected remains 
critical in the field of women’s health.
Initial attempts to address this question have focused 
on access to EC as an important factor in increasing usage. 
Clearly, given the limited time interval in which EC must 
be taken, easy access to the medication is essential. Prior 
to approval of over-the-counter sale of the levonorgestrel 
regimen (plan B) by the FDA in 2006, several studies assessed 
the impact of increasing access to EC. A study published in 
2005 compared usage rates of EC among women who were 
given levonorgestrel tablets to keep at home, those who could 
access the medication via a pharmacy without a prescription, 
and those who could only access the medication by presenting 
to a clinic.46 The authors demonstrated that women who were 
given the medication to keep at home were twice as likely to 
use it compared with the other two groups, even though the 
frequency of unprotected intercourse in the three groups was 
similar. Interestingly, women who had access to EC through a 
pharmacy were not significantly more likely to utilize EC than 
those who had to present to a clinic to obtain the medication. 
A recent meta-analysis describing the results of many similar 
trials corroborated this finding, demonstrating that increased 
access to EC does increase use.44 One of the biggest concerns 
regarding increasing access to EC is whether such access will 
promote sexually risky behavior and increase the incidence 
of STIs. However, several studies have now demonstrated 
that advance provision of EC to women does not increase 
the incidence of unprotected intercourse, decrease the rate of 
consistent contraceptive use, or increase the rate of STIs.46–51 
Thus, such arguments against making EC widely accessible 
appear unwarranted.
Although access to EC has consistently improved over 
the years, some significant limitations still exist. In the US, 
only women over the age of 16 years are able to access EC 
without a prescription. This significantly limits access to a 
population where unintended pregnancy rates are the  highest, 
because approximately 80% of teenage pregnancies are 
unintended and contribute 25% or more to the unplanned 
pregnancy rate annually in the US.52 Furthermore, many 
teens and young adults report that the current cost (generally 
around US$50 when purchased in a pharmacy) is a significant 
impediment to accessing EC. In a study performed in New 
York City where indepth interviews were conducted with 
teens and young adults, many respondents expressed disbe-
lief that anyone would pay US$ 50 to obtain EC,  especially 
when “it might not even work.”53 Thus, eliminating the age 
restriction to allow access to EC without a prescription for 
all women, and working to reduce the current cost of EC in 
pharmacies are two major components that must be addressed 
in order to provide widespread access to EC. However, 
although multiple studies have demonstrated that increased 
access to EC does increase use, such studies have also clearly 
demonstrated that increased use of EC is not translating 
into a notable decrease in the unintended  pregnancy rate.44 
Thus, other barriers aside from access must be at work 
in impeding the realization of the true potential of EC to 
decrease unintended pregnancy rates.
One such barrier that has more recently come to light 
is the limited knowledge that many people have in regards 
to EC. In a survey conducted in California in 2003 by the 
Kaiser Family Foundation, where over 1000 men and women 
aged 15–44 years participated, several of these knowledge 
gaps were highlighted.54 For example, when asked if they 
had heard of EC or the “morning-after pill,” the majority of 
respondents (78%) indicated that they were familiar with EC. 
However, when asked whether there was something a woman 
could do to prevent pregnancy after unprotected intercourse 
or contraceptive failure, only about one third of adults indi-
cated that they understood that EC could be used in this situ-
ation. This underscores the fact that, although most men and 
women of reproductive age are familiar with the term EC or 
the “morning-after pill,” the majority of them do not actually 
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understand what it does. Furthermore, this survey, as well 
as other research, has demonstrated that there is  significant 
 confusion between EC and RU-486 or  mifepristone, 
 commonly referred to as the “abortion pill” by the lay pub-
lic in the US.53–55 In the Kaiser Family Foundation survey, 
respondents were asked whether the  following  statement was 
true or false: “Emergency  contraceptive pills are another term 
for RU-486, the ‘abortion pill’.” Fifty percent of participants 
indicated that they thought this was a true statement.54 Unfor-
tunately, several years later and following the change of the 
levonorgestrel regimen to over-the-counter status by the FDA, 
such misconceptions are still fairly common.
A recent study conducted among adolescents aged 
15–21 years in New York City in 2010 mirrored the findings 
of the Kaiser Family Foundation in that the majority of 
respondents, while stating that they were familiar with EC 
or Plan B, frequently still said no when asked if there was 
something they could do to prevent pregnancy after sexual 
intercourse.53 Many also still confused EC with RU-486. 
Additionally, a prominent trend noted by the investigators 
conducting the interviews was that there was “a clear 
disconnect between the desire [of teens] not to be pregnant 
and the willingness to take proactive measures to prevent 
pregnancy.”53 Other studies have reflected the same belief. 
When determining the proportion of women who became 
unintentionally pregnant during trials assessing the use of 
EC, under 30% of women actually used EC in the menstrual 
cycle in which they became pregnant, even when EC was 
readily available. Responses given for the failure to use EC 
demonstrated that many women fail to recognize the risk of 
pregnancy, even when the timing of intercourse is close to 
ovulation. These findings point to the need for significant 
public education campaigns to educate women better 
regarding how and when to use EC if the rates of unintended 
pregnancy and abortion are actually to be decreased.
Finally, not only are public awareness campaigns 
 necessary, but improved counseling by providers of women’s 
health is also paramount to educate women better about EC. 
Currently, of women familiar with EC, only 10% learned 
about it from a health professional.54 Even if women had a 
gynecologic visit within the past year, only 13% report that 
their physician discussed EC. Surveys among practicing 
physicians support this general lack of counseling. In a survey 
from 2001, only 25% of gynecologists and 14% of general 
practice physicians report discussing EC as a backup method 
of contraception “always” or “most” of the time.56 However, 
such counseling from physicians likely plays a significant 
role in whether women actually are motivated to use EC 
after unprotected intercourse or contraceptive failure. The 
majority of women reported being more likely to take EC if a 
doctor had informed and counseled them about this option.54 
Furthermore, research demonstrates that many  primary care 
physicians themselves require further education about pre-
scribing EC, because surveys among physicians often cite 
lack of familiarity, concern with increasing rates of STIs, and 
concern about potential teratogenicity as barriers to routine 
prescribing.57–60 In a recent survey of pediatric emergency 
room physicians, although the vast majority had prescribed 
EC at some point in the past, most reported prescribing EC 
five or fewer times.60 Most physicians cited one or more 
barriers to EC prescribing, including concern about lack 
of follow-up, time constraints, lack of clinical resources, 
discouraging regular contraceptive use, and concern about 
birth defects. Furthermore, 43% of respondents were not 
able to answer half of the knowledge-based questions in the 
survey correctly.
Given that teens younger than 17 years in the US still 
require a prescription to obtain EC and the emergency room is 
a likely place for them to go, it is concerning that a significant 
number of pediatric ER physicians have limited knowledge 
regarding appropriate prescribing and unfounded concerns 
about barriers with EC. Further education of all practitioners 
who routinely provide care to women of reproductive age is 
vital, with special emphasis on the timing of EC, its safety 
and efficacy, even if taken multiple times, and its lack of 
association with teratogenicity.
Future directions
COX-2 inhibitors
Utilizing cyclo-oxygenase (COX)-2 inhibitors to delay or 
 prevent ovulation for the purpose of EC is another research 
focus on the horizon. Prostaglandins are known to be 
 important in many aspects of ovulation, such as cumulus 
expansion and augmentation of protease activity, which 
leads to extracellular matrix degradation.61 Both of these 
processes are critical to successful ovulation, and COX-2 
enzymes are essential in the production of prostaglandins 
within the ovarian follicle.
In a recent study by Hester et al primates were treated with 
meloxicam, a COX-2 inhibitor, for 5 consecutive days  starting 
either in the mid follicular, late follicular, or  periovulatory 
phase of the menstrual cycle.61 The investigators  demonstrated 
that ovulation was blocked in 67% of cycles when meloxicam 
was administered in the mid follicular phase, 100% of cycles 
when administered in the late follicular phase, and in only 
50% of cycles when administered in the periovulatory phase. 
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In the study, the ovaries were removed following treatment 
with meloxicam, and the investigators demonstrated that the 
majority of the follicles still retained their oocyte, suggest-
ing that inhibition of oocyte release, either through failure 
of cumulus expansion or failure of the breakdown of the 
follicular wall, may be the mechanism through which the 
COX-2 inhibitor works.61
In a similar study conducted in humans, women who were 
surgically sterilized were treated with either 15 mg or 30 mg 
meloxicam for 5 days in the late follicular phase, starting 
when the lead follicle was noted to be 18 mm on ultrasound.62 
When administered at the 30 mg dose, meloxicam was 
demonstrated to inhibit follicle rupture  during the six-day 
observation period in 45.5% of cycles, and to cause ovulatory 
dysfunction (defined as follicle rupture not preceded by 
a luteinizing hormone peak or preceded by a blunted 
luteinizing hormone peak or not followed by an appropriate 
progesterone rise) in an additional 45.5% of cycles. Interest-
ingly, even when meloxicam was administered after the peak 
of the luteinizing hormone surge, it was still able to cause 
ovulatory dysfunction in 75% (six of eight) of women. The 
authors concluded that this may be the biggest benefit of 
COX-2 inhibitors over levonorgestrel, because it has been 
demonstrated that levonorgestrel is no longer effective at 
delaying ovulation when administered after the peak of the 
luteinizing hormone surge.62 Finally, when administered in 
conjunction with 1.5 mg levonorgestrel once the lead follicle 
is .18 mm, Massai et al have shown that 15 mg of meloxicam 
can increase the incidence of failed follicular rupture from 
16% to 39%.43 Thus, COX-2 inhibitors may ultimately play 
a role, either independently or when used in conjunction 
with hormonal methods, in increasing the efficacy of EC. 
However, large-scale clinical trials demonstrating efficacy in 
preventing pregnancy are necessary before COX-2 inhibitors 
become a potential clinical option.
Conclusion
Emergency contraception is currently accessible in over 
140 countries.27 Emergency contraceptive options, such as 
the levonorgestrel regimen, selective progesterone  receptor 
modulators, the Yuzpe regimen, and insertion of a  copper 
IUD, have all been demonstrated to be efficacious in 
 preventing unplanned pregnancies following unprotected or 
underprotected intercourse. However, despite the increased 
availability of EC over the past decade, no study to date has 
been able to demonstrate a reduction in unplanned preg-
nancy and/or abortion rates worldwide. This finding is felt 
to be at least partly due to an underutilization of current 
EC methods. Thus, it is imperative that future research not 
only addresses the efficacy of various methods of EC, but 
also that it focuses on how to advance awareness and bet-
ter educate women about accessing and utilizing EC when 
necessary, if a reduction in the abortion rate worldwide is 
to be realized.
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